US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
MXPA01011279A
(es)
|
1999-05-07 |
2002-07-02 |
Genentech Inc |
Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
|
US7527787B2
(en)
*
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
US7550143B2
(en)
*
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
KR20020027490A
(ko)
*
|
1999-07-12 |
2002-04-13 |
제넨테크, 인크. |
Cd20에 결합하는 길항제를 사용한 외래 항원에 대한면역 반응 차단 방법
|
EP1255558B1
(en)
*
|
2000-02-16 |
2006-06-14 |
Genentech, Inc. |
Anti-april antibodies and hybridoma cells
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20100056762A1
(en)
*
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
EA200601861A1
(ru)
*
|
2001-08-03 |
2007-02-27 |
Дженентек, Инк. |
ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
US8420086B2
(en)
*
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
AU2011226858B2
(en)
*
|
2002-12-16 |
2015-01-22 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
EP1944320A1
(en)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
US20040202666A1
(en)
*
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
JP4874090B2
(ja)
*
|
2003-01-31 |
2012-02-08 |
イミューノメディクス、インコーポレイテッド |
治療薬および診断薬を投与するための方法および組成物
|
MXPA05010778A
(es)
|
2003-04-09 |
2005-12-12 |
Genentech Inc |
Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
|
WO2005000901A2
(en)
*
|
2003-05-09 |
2005-01-06 |
Duke University |
Cd20-specific antibodies and methods of employing same
|
AR044388A1
(es)
*
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
JP4745242B2
(ja)
*
|
2003-05-20 |
2011-08-10 |
アプライド モレキュラー エボリューション,インコーポレイテッド |
Cd20結合分子
|
AU2004240782B2
(en)
*
|
2003-05-23 |
2011-04-21 |
Crucell Holland B.V. |
Production of recombinant IGM in per.C6 cells
|
MXPA05013117A
(es)
*
|
2003-06-05 |
2006-03-17 |
Genentech Inc |
Terapia de combinacion para trastornos de celulas-b.
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
EP1651663B1
(en)
*
|
2003-08-08 |
2017-05-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
WO2005061542A2
(en)
*
|
2003-12-19 |
2005-07-07 |
Genentech, Inc. |
Detection of cd20 in transplant rejection
|
MXPA06006864A
(es)
*
|
2003-12-19 |
2006-08-23 |
Genentech Inc |
Deteccion de cd20 en la terapia de enfermedades autoinmunes.
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
WO2006107617A2
(en)
*
|
2005-04-06 |
2006-10-12 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
US7901680B2
(en)
*
|
2005-10-19 |
2011-03-08 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) vaccines for cancer therapy
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
US8003111B2
(en)
*
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
US8034352B2
(en)
*
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
EP1742660A2
(en)
*
|
2004-04-16 |
2007-01-17 |
Genentech, Inc. |
Treatment of disorders
|
KR20070012408A
(ko)
*
|
2004-04-16 |
2007-01-25 |
제넨테크, 인크. |
B 세포 고갈을 증대시키는 방법
|
JP2007536246A
(ja)
*
|
2004-05-05 |
2007-12-13 |
ジェネンテック・インコーポレーテッド |
自己免疫疾患の予防法
|
EP2425847A1
(en)
*
|
2004-05-20 |
2012-03-07 |
ZymoGenetics, Inc. |
Methods of treating cancer using IL-21 and monoclonal antibody therapy
|
US9228008B2
(en)
*
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
EP2374815A1
(en)
*
|
2004-05-28 |
2011-10-12 |
IDEXX Laboratories, Inc. |
Canine CD20 compositions
|
AR049200A1
(es)
*
|
2004-06-04 |
2006-07-05 |
Genentech Inc |
Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
|
CA2568336A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Genentech, Inc. |
Method for treating lupus
|
JP2008505148A
(ja)
*
|
2004-07-09 |
2008-02-21 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療
|
US20060062787A1
(en)
*
|
2004-07-22 |
2006-03-23 |
Genentech, Inc. |
Method for treating Sjogren's syndrome
|
WO2006020114A2
(en)
|
2004-08-04 |
2006-02-23 |
Applied Molecular Evolution, Inc. |
Variant fc regions
|
WO2006031370A2
(en)
*
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US20060110387A1
(en)
*
|
2004-10-05 |
2006-05-25 |
Genentech, Inc. |
Method for treating vasculitis
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
AU2005313971B2
(en)
*
|
2004-12-08 |
2011-10-13 |
Immunomedics, Inc. |
Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
|
US20060188495A1
(en)
*
|
2005-01-13 |
2006-08-24 |
Genentech, Inc. |
Treatment method
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US8101179B2
(en)
*
|
2005-03-31 |
2012-01-24 |
Biomedics Inc. |
Anti-CD20 monoclonal antibody
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
JP3989936B2
(ja)
*
|
2005-04-07 |
2007-10-10 |
進 須永 |
抗腫瘍剤及び新規dnアーゼ
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
EP1902320B1
(en)
*
|
2005-05-20 |
2010-03-10 |
Genentech, Inc. |
Pretreatment of a biological sample from an autoimmune disease subject
|
CA2608818A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Genentech, Inc. |
Method of producing antibodies with modified fucosylation level
|
RS54088B1
(en)
|
2005-07-25 |
2015-10-30 |
Emergent Products Development Seattle Llc |
B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
|
CN101291954B
(zh)
*
|
2005-08-26 |
2013-03-27 |
罗氏格黎卡特股份公司 |
具有改变的细胞信号传导活性的修饰的抗原结合分子
|
US8497258B2
(en)
|
2005-11-12 |
2013-07-30 |
The Regents Of The University Of California |
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
AU2006318539B2
(en)
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
WO2007102200A1
(ja)
*
|
2006-03-07 |
2007-09-13 |
Osaka University |
抗cd20モノクローナル抗体
|
US7727525B2
(en)
*
|
2006-05-11 |
2010-06-01 |
City Of Hope |
Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
|
KR101571027B1
(ko)
|
2006-06-12 |
2015-11-23 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
효과기 기능을 갖는 단일쇄 다가 결합 단백질
|
JP5605895B2
(ja)
|
2006-07-04 |
2014-10-15 |
ゲンマブ エー/エス |
Copdを処置するためのcd20結合分子
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
CA2673725C
(en)
*
|
2006-12-20 |
2016-01-12 |
Mmr Information Systems, Inc. |
Antibodies and methods for making and using them
|
CA2675014C
(en)
*
|
2007-01-17 |
2016-03-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
EP2120915B1
(en)
|
2007-01-22 |
2011-09-28 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
PE20090190A1
(es)
*
|
2007-03-23 |
2009-03-22 |
Smithkline Beecham Corp |
Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
KR101643514B1
(ko)
|
2007-07-09 |
2016-07-27 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
CN101809037B
(zh)
|
2007-07-31 |
2014-01-15 |
瑞泽恩制药公司 |
人cd20的人抗体及其使用方法
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
MX2010003099A
(es)
|
2007-09-21 |
2010-05-17 |
Univ California |
Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
|
EP2233149B1
(en)
|
2007-10-16 |
2016-02-10 |
ZymoGenetics, Inc. |
Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
|
KR20150008503A
(ko)
|
2007-10-30 |
2015-01-22 |
제넨테크, 인크. |
양이온 교환 크로마토그래피에 의한 항체 정제
|
AU2008342956A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Genentech, Inc. |
Therapy of rituximab-refractory rheumatoid arthritis patients
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
CN102083460A
(zh)
*
|
2008-01-18 |
2011-06-01 |
米迪缪尼有限公司 |
用于位点特异性偶联的半胱氨酸工程化抗体
|
JP5608100B2
(ja)
*
|
2008-02-08 |
2014-10-15 |
メディミューン,エルエルシー |
低下したFcリガンド親和性を有する抗IFNAR1抗体
|
CN102119175A
(zh)
*
|
2008-04-10 |
2011-07-06 |
Ibc药品公司 |
采用停靠与锁(dnl)技术制备具有增强的药物动力学的四聚细胞因子的模块方法
|
NZ588671A
(en)
*
|
2008-04-11 |
2012-11-30 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US20090269339A1
(en)
*
|
2008-04-29 |
2009-10-29 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
KR20150127300A
(ko)
|
2008-05-30 |
2015-11-16 |
엑스바이오테크, 인크. |
인터류킨-1 알파 항체 및 그의 사용 방법
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
MX2011000891A
(es)
*
|
2008-07-21 |
2011-06-01 |
Immunomedics Inc |
Variantes estructurales de anticuerpos para caracteristicas terapeuticas mejoradas.
|
US10927144B2
(en)
|
2008-08-14 |
2021-02-23 |
Genentech, Inc. |
Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
|
AU2014200771B2
(en)
*
|
2008-09-04 |
2016-05-26 |
Vet Therapeutics, Inc. |
Monoclonal antibodies
|
US8337842B2
(en)
*
|
2008-09-04 |
2012-12-25 |
Vet Therapeutics, Inc. |
Monoclonal antibodies
|
CA2734275A1
(en)
|
2008-09-10 |
2010-03-18 |
Genentech, Inc. |
Compositions and methods for the prevention of oxidative degradation of proteins
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
PL3903829T3
(pl)
|
2009-02-13 |
2023-08-14 |
Immunomedics, Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
EP2396416A4
(en)
*
|
2009-02-16 |
2013-02-27 |
Synthon Biopharmaceuticals Bv |
HUMANIZED ANTI-CD20 ANTIBODIES AND METHOD FOR THEIR USE
|
CN105884903B
(zh)
*
|
2009-03-10 |
2019-12-06 |
贝勒研究院 |
靶向抗原呈递细胞的疫苗
|
WO2010110838A2
(en)
*
|
2009-03-25 |
2010-09-30 |
Vet Therapeutics Inc. |
Antibody constant domain regions and uses thereof
|
US20100247484A1
(en)
*
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
EP2435476A4
(en)
|
2009-05-27 |
2013-04-17 |
Synageva Biopharma Corp |
ANTIBODIES OBTAINED FROM BIRDS
|
US20120213705A1
(en)
*
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
KR20180010324A
(ko)
|
2009-08-11 |
2018-01-30 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
MX353186B
(es)
|
2009-09-03 |
2018-01-05 |
Genentech Inc |
Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
US20120213728A1
(en)
*
|
2009-10-30 |
2012-08-23 |
Merck |
Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris
|
EP2506881B1
(en)
|
2009-12-02 |
2024-03-06 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US9180186B2
(en)
|
2010-01-11 |
2015-11-10 |
Alexion Pharmaceuticals, Inc. |
Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
|
MX341687B
(es)
*
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
AR080155A1
(es)
*
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos anti-cd20 y su utilizacion
|
WO2011100538A1
(en)
|
2010-02-11 |
2011-08-18 |
Alexion Pharmaceuticals, Inc. |
Therapeutic methods using an ti-cd200 antibodies
|
US9616120B2
(en)
|
2010-03-04 |
2017-04-11 |
Vet Therapeutics, Inc. |
Monoclonal antibodies directed to CD20
|
CA2791560A1
(en)
*
|
2010-03-04 |
2011-09-09 |
Vet Therapeutics Inc. |
Monoclonal antibodies directed to cd20
|
AU2011223547B2
(en)
*
|
2010-03-04 |
2016-05-05 |
Vet Therapeutics, Inc. |
Monoclonal antibodies directed to CD52
|
CN102190728B
(zh)
*
|
2010-03-17 |
2014-07-02 |
永卓博济(上海)生物医药技术有限公司 |
一种人源化抗cd20单克隆抗体
|
BR112012021873B8
(pt)
|
2010-03-22 |
2021-09-14 |
Genentech Inc |
composição de matéria, artigo de manufatura, métodos para preparar uma composição, para aumentar a estabilidade de uma proteína em solução aquosa livre de polissorbato e para prevenir ou reduzir a agregação de uma proteína em solução aquosa livre de polissorbato
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
JP5947289B2
(ja)
|
2010-05-10 |
2016-07-06 |
アカデミア シニカAcademia Sinica |
抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
|
CN107596365A
(zh)
|
2010-06-18 |
2018-01-19 |
埃克斯生物科技公司 |
关节炎治疗
|
KR101924653B1
(ko)
|
2010-06-24 |
2018-12-03 |
제넨테크, 인크. |
단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
|
BR112013002535A2
(pt)
|
2010-08-03 |
2019-09-24 |
Hoffmann La Roche |
biomarcadores de leucemia linfocítica crônica (cll)
|
KR20160062200A
(ko)
|
2010-08-23 |
2016-06-01 |
엑스바이오테크, 인크. |
종양성 질병들에 대한 치료
|
EP3351559A3
(en)
|
2010-11-08 |
2018-10-31 |
F. Hoffmann-La Roche AG |
Subcutaneously administered anti-il-6 receptor antibody
|
DK3252076T3
(da)
|
2011-01-14 |
2019-12-02 |
Univ California |
Diagnostisk anvendelse af antistoffer mod ror-1-protein
|
EP2680884B1
(en)
|
2011-02-28 |
2018-01-17 |
F. Hoffmann-La Roche AG |
Biological markers and methods for predicting response to b-cell antagonists
|
EP3138581B1
(en)
*
|
2011-03-17 |
2019-01-02 |
The University of Birmingham |
Re-directed immunotherapy
|
US9724409B2
(en)
|
2011-04-01 |
2017-08-08 |
Xbiotech, Inc. |
Treatment of inflammatory skin disease
|
JP2014512184A
(ja)
*
|
2011-04-07 |
2014-05-22 |
メモリアル スローン−ケタリング キャンサー センター |
抗腫瘍抗体−腫瘍抑制因子融合タンパク質組成物およびがんの処置のための使用方法
|
EP2714733B1
(en)
|
2011-05-21 |
2019-01-23 |
MacroGenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
US20140234298A1
(en)
|
2011-07-06 |
2014-08-21 |
Morphosys Ag |
Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
|
WO2013063186A2
(en)
|
2011-10-26 |
2013-05-02 |
Novartis Animal Health Us, Inc. |
Monoclonal antibodies and methods of use
|
US20130302274A1
(en)
*
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
CN104125963B
(zh)
|
2011-12-22 |
2018-08-17 |
弗·哈夫曼-拉罗切有限公司 |
使用离子交换膜层析改进下游蛋白质纯化步骤的方法
|
WO2013109904A1
(en)
*
|
2012-01-19 |
2013-07-25 |
University Of Miami |
Compositions, methods and kits for treatment of cancer and autoimmune diseases
|
JP2015506950A
(ja)
|
2012-01-31 |
2015-03-05 |
ジェネンテック, インコーポレイテッド |
抗ig−em1’抗体およびそれを用いる方法
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
JP2015517511A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd37抗体とice(イフォスファミド、カルボプラチン、エトポシド)の併用
|
WO2013173687A1
(en)
|
2012-05-18 |
2013-11-21 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
CN102863531A
(zh)
*
|
2012-07-31 |
2013-01-09 |
张爱晖 |
一种抗cd20单克隆抗体及其制备方法和用途
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
AU2013306098A1
(en)
|
2012-08-18 |
2015-02-12 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
WO2014031762A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
WO2014089354A1
(en)
|
2012-12-07 |
2014-06-12 |
The Regents Of The University Of California |
Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
BR112015013444B1
(pt)
|
2012-12-13 |
2022-11-01 |
Immunomedics, Inc |
Uso de um imunoconjugado
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US8877202B2
(en)
|
2013-02-07 |
2014-11-04 |
Immunomedics, Inc. |
Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
BR112015026021A2
(pt)
|
2013-04-17 |
2017-07-25 |
Signal Pharm Llc |
terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
|
JP6389241B2
(ja)
|
2013-04-17 |
2018-09-12 |
シグナル ファーマシューティカルズ,エルエルシー |
癌を治療するためのTORキナーゼ阻害剤及びIMiD化合物を含む組合せ療法
|
KR102240356B1
(ko)
|
2013-04-17 |
2021-04-14 |
시그날 파마소티칼 엘엘씨 |
Tor 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
|
US9119854B2
(en)
|
2013-05-03 |
2015-09-01 |
Celgene Corporation |
Methods for treating cancer using combination therapy
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
EP3041484B1
(en)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015219495B2
(en)
|
2014-02-21 |
2019-11-21 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
EP3110445A4
(en)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
TW201623331A
(zh)
*
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
CN103880958B
(zh)
*
|
2014-03-27 |
2016-01-20 |
安徽大学 |
抗cd20抗原的抗体l4h6及其应用
|
CN103880957B
(zh)
*
|
2014-03-27 |
2016-01-20 |
安徽大学 |
抗cd20抗原的抗体l1h1及其应用
|
SG11201608194VA
(en)
|
2014-04-03 |
2016-10-28 |
Igm Biosciences Inc |
Modified j-chain
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
KR102576850B1
(ko)
|
2014-05-27 |
2023-09-11 |
아카데미아 시니카 |
박테로이드 기원의 푸코시다제 및 이의 사용 방법
|
KR20170003720A
(ko)
|
2014-05-27 |
2017-01-09 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
CA2950433A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
JP6899321B2
(ja)
|
2014-09-08 |
2021-07-07 |
アカデミア シニカAcademia Sinica |
糖脂質を使用するヒトiNKT細胞活性化
|
HUE050831T2
(hu)
|
2014-11-17 |
2021-01-28 |
Regeneron Pharma |
Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
|
EP3223845B1
(en)
*
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
WO2016126611A1
(en)
|
2015-02-02 |
2016-08-11 |
The University Of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
|
SG11201707144VA
(en)
|
2015-03-04 |
2017-09-28 |
Igm Biosciences Inc |
Cd20 binding molecules and uses thereof
|
ES2736106T3
(es)
*
|
2015-03-10 |
2019-12-26 |
Bristol Myers Squibb Co |
Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
PE20221007A1
(es)
|
2015-06-24 |
2022-06-15 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad disenada
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
EP3313443B9
(en)
|
2015-06-25 |
2023-10-04 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
CA2999138C
(en)
|
2015-09-21 |
2024-05-21 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
EP3355913A1
(en)
|
2015-09-30 |
2018-08-08 |
IGM Biosciences A/S |
Binding molecules with modified j-chain
|
EP3356401B1
(en)
|
2015-09-30 |
2020-06-24 |
IGM Biosciences, Inc. |
Binding molecules with modified j-chain
|
CN114031689A
(zh)
|
2015-10-02 |
2022-02-11 |
豪夫迈·罗氏有限公司 |
双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
ES2873846T3
(es)
|
2015-11-19 |
2021-11-04 |
Revitope Ltd |
Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
|
WO2017087843A1
(en)
*
|
2015-11-20 |
2017-05-26 |
Immungene, Inc |
Methods of treating proliferative diseases using engineered antibody-interferon fusion molecules
|
CA3007419A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
KR102131544B1
(ko)
*
|
2016-02-18 |
2020-07-07 |
엘랑코 유에스 인코포레이티드 |
키메라 개 항-cd20 항체
|
EP3423593A1
(en)
|
2016-03-02 |
2019-01-09 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
|
TW201808978A
(zh)
|
2016-03-08 |
2018-03-16 |
中央研究院 |
N-聚醣及其陣列之模組化合成方法
|
AU2017257254B2
(en)
|
2016-04-27 |
2022-02-24 |
Immunomedics, Inc. |
Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
MA45715A
(fr)
|
2016-07-25 |
2019-05-29 |
Biogen Ma Inc |
Anticorps anti-hspa5 (grp78) et leurs utilisations
|
CN109963868B
(zh)
|
2016-08-22 |
2023-11-14 |
醣基生医股份有限公司 |
抗体、结合片段及使用方法
|
EP4252629A3
(en)
|
2016-12-07 |
2023-12-27 |
Biora Therapeutics, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
JOP20190155A1
(ar)
*
|
2016-12-21 |
2019-06-23 |
Novartis Ag |
مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
|
KR20190117579A
(ko)
|
2017-02-16 |
2019-10-16 |
엑스바이오테크, 인크. |
화농성 한선염의 치료
|
US10918734B2
(en)
|
2017-03-27 |
2021-02-16 |
Immunomedics, Inc. |
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
|
EP3600416B1
(en)
|
2017-03-30 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
JP7279011B2
(ja)
|
2017-07-10 |
2023-05-22 |
インターナショナル-ドラッグ-ディベロップメント-バイオテック |
抗cd20抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗cd19抗体を用いるb細胞悪性の治療
|
CN107384963A
(zh)
*
|
2017-07-31 |
2017-11-24 |
山东兴瑞生物科技有限公司 |
一种可控型cd20嵌合抗原受体修饰t细胞的制备方法及其应用
|
WO2019028125A1
(en)
|
2017-08-01 |
2019-02-07 |
Ab Studio Inc. |
BISPECIFIC ANTIBODIES AND USES THEREOF
|
WO2019094931A1
(en)
*
|
2017-11-10 |
2019-05-16 |
Actinium Pharmaceuticals, Inc. |
Combination therapy for treatment of a hematological disease
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
CA3087529A1
(en)
|
2018-01-03 |
2019-07-11 |
Palleon Pharmaceuticals Inc. |
Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
|
US20210070871A1
(en)
|
2018-04-25 |
2021-03-11 |
Prometheus Biosciences, Inc. |
Optimized anti-tl1a antibodies
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
AU2019331024A1
(en)
|
2018-08-31 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
|
WO2020064847A1
(en)
|
2018-09-26 |
2020-04-02 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
RU2724469C2
(ru)
*
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
EP3883634A1
(en)
|
2018-11-19 |
2021-09-29 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
CN113660956A
(zh)
*
|
2019-01-28 |
2021-11-16 |
Ab诊疗公司 |
双特异性抗体及其用途
|
AU2020228383A1
(en)
|
2019-02-27 |
2021-09-23 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
|
MX2021012032A
(es)
|
2019-04-01 |
2021-11-03 |
Genentech Inc |
Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
|
US20200392230A1
(en)
*
|
2019-05-14 |
2020-12-17 |
Qlb Biotherapeutics |
Bispecific anti-cd3 x cd20 antibodies and uses thereof
|
US20220380742A1
(en)
*
|
2019-07-03 |
2022-12-01 |
Palleon Pharmaceuticals Inc. |
Sialidase-cd20-antibody fusion proteins and methods of use thereof
|
JP2021059499A
(ja)
|
2019-10-03 |
2021-04-15 |
日本全薬工業株式会社 |
イヌcd20に対するモノクローナル抗体又は抗体フラグメント
|
KR20220103721A
(ko)
|
2019-10-24 |
2022-07-22 |
프로메테우스 바이오사이언시즈, 인크. |
Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
|
EP4309722A2
(en)
|
2019-12-13 |
2024-01-24 |
Biora Therapeutics, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
IL300701A
(en)
*
|
2020-08-17 |
2023-04-01 |
Atb Therapeutics |
Immunotoxin-containing immunotoxin-containing or renase
|
CN112851810B
(zh)
*
|
2021-01-23 |
2021-09-07 |
北京科跃中楷生物技术有限公司 |
Cd20抗体及其治疗癌症的应用
|
WO2022239720A1
(ja)
|
2021-05-10 |
2022-11-17 |
公益財団法人川崎市産業振興財団 |
抗原への結合親和性を低減させた抗体
|
WO2023016488A1
(zh)
|
2021-08-13 |
2023-02-16 |
昆山新蕴达生物科技有限公司 |
一种基于微管抑制剂的抗体偶联药物
|
CN116120455B
(zh)
*
|
2021-08-23 |
2023-11-07 |
东莞市朋志生物科技有限公司 |
一种抗ca15-3蛋白的重组抗体
|
WO2023024949A1
(zh)
|
2021-08-24 |
2023-03-02 |
昆山新蕴达生物科技有限公司 |
一种由可断裂连接子偶联的抗体偶联药物
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
KR20230119856A
(ko)
*
|
2022-02-08 |
2023-08-16 |
연세대학교 산학협력단 |
신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
|
WO2024040149A2
(en)
*
|
2022-08-17 |
2024-02-22 |
The Texas A&M University System |
Chicken-derived cd20 antibodies with potent b cell depletion activity
|